Stockscreener 앱 받기
6.03
13.61%
-0.95
시간 외 거래:
5.68
-0.35
-5.80%
Portage Biotech Inc 주식(PRTG)의 최신 뉴스
Small Cap Stocks To Add to Your WatchlistMarch 29th - MarketBeat
Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-High - Asianet Newsable
Portage Biotech Insider Buyers See Boost After Market Cap Rose US$9.0m - simplywall.st
Promising Biotech Stocks To Watch Now – March 28th - Defense World
Portage Biotech (NASDAQ:PRTG) vs. Cytokinetics (NASDAQ:CYTK) Head-To-Head Survey - Defense World
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
Why Is Portage Biotech Stock Skyrocketing Friday? - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher - Benzinga
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading - Stocks Telegraph
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma - Marketscreener.com
Portage Biotech presents preclinical data for PORT-7 - TipRanks
Portage Biotech reports promising mesothelioma treatment data By Investing.com - Investing.com Australia
Portage Reports 'Promising' Preclinical Results in Mesothelioma - MarketScreener
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Portage Biotech Announces Promising Preclinical Results for PORT-7 in Mesothelioma - TipRanks
Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7 - MarketScreener
Portage Biotech reports promising mesothelioma treatment data - Investing.com
Portage Biotech stock soars on promising preclinical data - Investing.com
Portage Biotech stock soars on promising preclinical data By Investing.com - Investing.com Canada
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times
Game-Changing Mesothelioma Treatment: New Drug Achieves 90% Tumor Reduction in Latest Study - Stock Titan
Portage Biotech Inc. Announces New Director Compensation Plan and Stock Option Grants - TipRanks
Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6 - Nasdaq
Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments - Marketscreener.com
Portage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy Approach - TipRanks
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial - The Manila Times
Major Milestone: Portage Biotech's Novel Cancer Drug Enters Final Trial Phase - StockTitan
Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big Opportunity - MSN
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange - Newsfile
Portage Biotech granted Nasdaq compliance extension By Investing.com - Investing.com Nigeria
Portage Biotech receives extension from Nasdaq to attain listing compliance - MSN
Portage Biotech granted Nasdaq compliance extension - MSN
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - The Manila Times
Portage Biotech Granted Nasdaq Compliance Extension - TipRanks
Portage Biotech, Inc. Receives Extension to Regain Nasdaq Compliance Following Acceptance of Compliance Plan - Nasdaq
Nasdaq Grants Portage Biotech Critical 18-Month Lifeline to Secure Exchange Status - StockTitan
Hepatocellular Carcinoma Pipeline 2024: Latest FDA Approvals, - openPR
What is the investor’s view on Portage Biotech Inc (PRTG)? - US Post News
Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement - Stocks Telegraph
Portage Biotech Announces Completion of $2.15 Million Private Financing - The Manila Times
Portage Biotech Secures $2.15 Million in Private Financing - TipRanks
Portage Biotech, Inc. Completes $2.15 Million Private Placement to Support Corporate Growth - Nasdaq
Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement - StockTitan
Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Here’s What Happened - Defense World
Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc - Marketscreener.com
Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics with New CEO - TipRanks
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company - The Manila Times
1.23%
1.63%
자본화:
|
볼륨(24시간):